KWA
RUBY

KCS Wealth Advisory’s Rubius Therapeutics, Inc RUBY Stock Holding History

KCS Wealth Advisory’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,790
Closed -$14.1K – 430
2019
Q3 		$14.1K Buy
+1,790
New +$20.9K 0.01% 329

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

KCS Wealth Advisory's RUBY Position: Q4 2019 in Review

KCS Wealth Advisory sold out of Rubius Therapeutics, Inc (RUBY) in Q4 2019, closing a stake of 1,790 shares — an estimated $14.1K sold.

KCS Wealth Advisory first reported a position in RUBY in Q3 2019 and held it in 1 quarter. The position peaked at $14.1K in Q3 2019. 76 funds tracked by Wall St. Rank hold RUBY as of Q4 2019.

  • KCS Wealth Advisory reported no remaining Rubius Therapeutics, Inc position as of Q4 2019 after selling out during the quarter.
  • KCS Wealth Advisory sold 1,790 Rubius Therapeutics, Inc shares in Q4 2019, an estimated $14.1K.
  • KCS Wealth Advisory first reported a position in Rubius Therapeutics, Inc in Q3 2019 and held it in 1 quarter.
  • KCS Wealth Advisory's Rubius Therapeutics, Inc position peaked at $14.1K in Q3 2019.
  • 76 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q4 2019.

Based on KCS Wealth Advisory's 13F filing for Q4 2019, filed 15 Jan 2020.